Skip to main content
Medical information Clinical review pending

Genetic Testing

GUCY1A3 Gene Moyamoya Type 6 with Achalasia Genetic Test

Genetic test for mutations in the GUCY1A3 gene associated with Moyamoya disease and Achalasia, using Next Generation Sequencing (NGS).

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or Saliva sample. Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No specific fasting is required. Inform the laboratory of any medications you are taking. A clinical history and genetic counseling session, including a family pedigree chart, are recommended before the test.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the GUCY1A3 Gene Moyamoya Type 6 with Achalasia Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Symptoms suggestive of Moyamoya disease (e.g., recurrent strokes, TIAs).
  • ✓Symptoms suggestive of Achalasia (e.g., difficulty swallowing, regurgitation).
  • ✓Family history of Moyamoya disease or related vascular disorders.
  • ✓Individuals seeking genetic risk assessment for these conditions.
02

In plain language

What this test helps you understand

Identifies genetic variations in the GUCY1A3 gene associated with Moyamoya disease and Achalasia, aiding in diagnosis and risk assessment.
The GUCY1A3 Gene Moyamoya Type 6 with Achalasia NGS Genetic DNA Test is designed to identify specific genetic variations in the GUCY1A3 gene. Mutations in this gene have been linked to an increased risk of developing certain vascular conditions, including Moyamoya disease and Achalasia. This test utilizes advanced Next Generation Sequencing (NGS) technology for accurate detection of these genetic changes.

This test specifically looks for variations in the GUCY1A3 gene. Moyamoya disease is a rare condition affecting blood vessels in the brain, potentially leading to strokes or TIAs. Achalasia is a disorder impacting the esophagus, causing difficulty swallowing.

Understanding your genetic predisposition can be crucial for managing health risks and making informed decisions about preventative care and treatment options. Discussing the results with a healthcare professional and genetic counselor is essential for proper interpretation in the context of your personal and family medical history.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific fasting is required. Inform the laboratory of any medications you are taking. A clinical history and genetic counseling session, including a family pedigree chart, are recommended before the test.
SampleBlood sample (EDTA tube) or Saliva sample. Confirm specific requirements with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) of the GUCY1A3 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects specific mutations in the GUCY1A3 gene. It does not rule out other genetic or non-genetic causes of Moyamoya disease or Achalasia. Not all GUCY1A3 mutations are detected by this panel. Results must be interpreted in a clinical context.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Moyamoya disease is a rare condition where blood vessels in the brain become narrowed, potentially leading to reduced blood flow and increased risk of stroke.
Achalasia is a disorder affecting the esophagus, the tube that carries food from the throat to the stomach. It makes it difficult for food and liquid to pass into the stomach.
Individuals with symptoms of Moyamoya disease or Achalasia, or those with a family history of these conditions, may benefit from this test.
Results are interpreted by genetic specialists and should be discussed with your doctor or a genetic counselor to understand their implications for your health.
Yes, genetic counseling before and after testing is highly recommended to understand the test, its implications, and potential results.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp